Central Nervous System

Aiming for the social reintegration of patients with psychiatric
and neurological disorders

Diseases of the central nervous system are also called psychiatric and neurological disorders. Since the causes and fundamental treatments for these conditions have not been fully understood, it is a challenge to create new drugs in this area, even for companies that have produced innovative medicines in the past. Patients and their families are hoping for drugs that can serve as new solutions for central nervous system disorders.

After more than 20 years of research and development in this area, Otsuka Pharmaceutical launched the world's first antipsychotic drug that is a dopamine D2 receptor partial agonist. It has few side effects and can be taken for sustained periods without worries. It provides those suffering from psychiatric and neurological disorders with a pharmaceutical innovation that can enable recovery without relapse.

In order to take on the challenge of creating new drugs, a company needs not only enthusiasm, passion, and curiosity, but also new ideas discovered by taking the untraveled paths. As a pioneer with a venture spirit, Otsuka aims to further assist patients and their families around the world. By working with global partners in the field of central nervous system disease, Otsuka is developing innovative new drugs for psychiatric and neurological disorders, and is taking on the challenge of introducing new technologies and new dosage formats to ensure reliable medication delivery.

Central Nervous System Diseases

Many central nervous system disorders lie in brain function. These disorders include schizophrenia and the manic symptoms of bipolar disorder, major depressive disorder, anxiety disorders that lead to behavioral and psychological impairment, as well as adjustment disorders that interfere with work, study and social life. Epilepsy is a chronic disease of the brain that causes repeated seizures. Then, there is Parkinson's disease, which is now recognized as a brain disorder. Schizophrenia, which involves an imbalance of messenger chemicals that convey information in the brain, is representative of central nervous system disease. It is an endogenous mental disorder where patients experience ongoing disruption of the usual balance of emotions and thinking.

Global Partners

Medical contributions for over a decade on the co-development and co-marketing of antipsychotic drugs.

Bristol-Myers Squibb Company (US)

Established: 1887
Bristol-Myers Squibb is a global biopharmaceutical company which brings together a foundation as a large pharmaceutical company with a tradition, and a position as a cutting-edge biotechnology company.

“Aligning around the patients. There is no other job, in my mind, that is more fulfilling.”

UCB S.A. (Belgium)

Established: 1928
UCB is a global biopharmaceutical company researching, developing, and marketing pharmaceuticals and biotech products mainly in the fields of the central nervous system, immune system, and inflammation.

“The central nervous system is a very difficult area. Lundbeck thinks with a long-term perspective and is not fixated on short-term goals.”

H. Lundbeck A/S (Denmark)

Established: 1915
Lundbeck is one of the world’s leading pharmaceutical companies specializing in central nervous system disorders. Its products encompass disorders such as depression and anxiety, schizophrenia, epilepsy, and Huntington’s, Alzheimer’s and Parkinson’s diseases.